Abstract
Introduction
There is evidence that platelets are excessively activated or 'hyper-reactive' in patients with TIA and ischaemic stroke versus controls, [1] [2] [3] [4] [5] [6] [7] and excessively activated in patients with recently symptomatic versus asymptomatic carotid stenosis. [2-4;8,9] There is also evidence that short-term treatment with aspirinclopidogrel combination therapy is more effective than aspirin monotherapy at preventing microembolic signals (MES) on TCD, [10] and that combination therapy with aspirin-dipyridamole appears equally effective as aspirin-clopidogrel at reducing MES in recently symptomatic carotid stenosis patients. [11] There is an emerging literature to suggest that data from platelet function/reactivity monitoring may enhance our ability to predict the risk of recurrent vascular events and functional outcome in patients with vascular disease. [8, 12] Ischaemic heart disease patients on antiplatelet therapy deemed to have 'high on-treatment platelet reactivity' (HTPR) or 'non-responsiveness' on an ex vivo test of platelet function have been shown to have a higher risk of clinical outcome events than those without HTPR. [13] [14] [15] However, the definition of HTPR on various platelet function devices varies between studies. [13] [14] [15] [16] [17] [18] Preliminary, hypothesis-generating, subgroup data analysis from one study suggested that, compared with controls, the prevalence of HTPR reduced in patients with severe carotid stenosis who were followed up from the early (≤4 weeks) to late phase (≥ 3 months) after symptom onset or intervention. [7] To our knowledge, no adequately powered studies have compared the prevalence of ex vivo HTPR in whole blood between asymptomatic and early and late phase symptomatic carotid stenosis patients.
Prior studies have illustrated the potential role of MES detection on TCD in identifying asymptomatic and symptomatic carotid stenosis patients who may benefit most from enhanced medical or surgical therapy to prevent TIA or stroke. [19] [20] [21] [22] [23] [24] To our knowledge, simultaneous measurement of HTPR on a point-of-care (POC) device, the PFA-100, has not been performed in patients with asymptomatic versus symptomatic carotid stenosis, in conjunction with simultaneous quantification of cerebral MES.
The aims of this component of the Platelets And Carotid Stenosis (PACS) study
were to determine whether HTPR on a moderately high shear stress test of platelet reactivity was more common in patients with recently symptomatic than asymptomatic carotid stenosis, and to longitudinally assess HTPR status in symptomatic patients and specific subgroups. We also aimed to determine whether there was any relationship between HTPR status and the presence of MES detected on TCD (MES +ve) versus those without (MES -ve). We prospectively planned to assess whether there was any relationship between HTPR and the risk of recurrent vascular events during follow up in symptomatic patients. We hypothesised that recently symptomatic patients were more likely to have an increased prevalence of HTPR than their asymptomatic counterparts, and that the prevalence of HTPR would decrease in symptomatic patients during follow up after intensive medical and/or surgical intervention. We also hypothesised that HTPR status might be informative in certain patient subgroups stratified according to MES status (MES +ve vs. MES -ve).
Methods
Pilot 'symptomatic case' vs. 'asymptomatic case/control', and 'nested longitudinal studies in symptomatic patients' with moderate-severe carotid stenosis was performed. Consecutive eligible patients > 18 years old with asymptomatic or symptomatic moderate or severe carotid artery stenosis or carotid occlusion, identified on colour Doppler ultrasound using standardised velocity criteria, [25, 26] were recruited from the Rapid Access Stroke Prevention (RASP) Service, vascular surgery or general neurology clinics, and the neurology and vascular surgery wards and stroke service at AMNCH and St James's Hospitals between August 2007 and February 2010. Patients were included in the 'asymptomatic carotid stenosis group' if they were incidentally noted to have moderate (50 -69%) or severe (≥ 70%) carotid stenosis on colour Doppler ultrasound imaging (CDUS), e.g. after noting an audible carotid bruit or during work up for coronary artery disease. [9, 19] Subjects were considered to be asymptomatic if they never had a prior TIA or stroke in any vascular territory, or had not had a carotid-territory TIA or stroke within the preceding three years. All demographic and vascular risk factors, and information regarding medication intake was recorded prospectively.
Patients were included in the 'symptomatic carotid stenosis' group if they had a TIA or ischaemic stroke in the vascular territory supplied by a moderate or severe ipsilateral carotid stenosis or carotid occlusion within the preceding 4 weeks and the symptoms was attributed to the stenosed carotid artery of interest (early phase).
These patients were reassessed at least three months after symptom onset or after surgical or endovascular intervention (late phase). To establish the normal range of platelet function assays in the laboratory, a group of healthy controls of similar age and sex, with no history of known cerebrovascular disease, were recruited from the local population and from amongst the family members of the participating subjects. Controls had colour Doppler ultrasound of carotid and vertebral arteries (CDUS) to exclude asymptomatic ≥ 50% carotid stenosis prior to inclusion. Subjects were also excluded from the control group if they were on antiplatelets or NSAIDs, or had any other exclusion criteria that applied to patients.
Blood sampling and laboratory tests:
All subjects were rested for at least 20 minutes, and careful venepuncture was performed from a free-flowing vein using a sterile 21G Butterfly needle (Venisystems TM , Abbott, Ireland) and a Vacutainer ® system with a luer adaptor (Becton Dickinson Vacutainer Systems, UK). Venepuncture was performed using a standardised manner as described previously. [19] Platelet function/on-treatment reactivity was assessed with the PFA-100 ® , to measure C-ADP and C-EPI closure times in citrate-anticoagulated whole blood between 2 and 2.5 hours after venepuncture. The PFA-100 activates platelets by exposure to moderately high shear stress (5000 -6000 s -1 ) and biochemical stimulation with collagen and either epinephrine (C-EPI cartridge) or ADP (C-ADP cartridge). [28, 29] The time taken for activated platelets to occlude an aperture in the cartridge is called the closure time; the maximum closure time recorded by the device is 300 s, and we arbitrarily defined closure times above 300 s as 301 s for statistical analyses.
Transcranial Doppler ultrasound:
Bilateral simultaneous 1 hour-TCD recordings of the MCA were performed by one of two highly-experienced operators (JAK or WOT) with a Viassys Pioneer TC8080, as described previously. [19] Statistical Methods 
Assessment of Platelet Reactivity:
There were no significant differences in median C-EPI or C-ADP closure times between the entire asymptomatic vs. early or late symptomatic groups, regardless of antiplatelet treatment regimens (Table 2 ). There were no differences in the prevalence of HTPR between the subgroups of asymptomatic vs. early or late phase symptomatic patients who were on aspirin or clopidogrel overall. However, the prevalence of aspirin-HTPR on the C-EPI cartridge was lower in the 'late symptomatic postintervention subgroup' than in the asymptomatic carotid stenosis subgroup on aspirin monotherapy (10% vs. 50%, p = 0.03; Table 2 ). There were no significant differences in vascular risk factors between these subgroups.
Amongst all symptomatic patients with longitudinal data in both the early and late phases after symptom onset or intervention, median C-EPI closure times increased from the early to late phases (143s vs. 203s, p = 0.03; Table 3a ). Amongst Table 3a ). There was a significant reduction in aspirin-HTPR between the early and late postintervention phases in symptomatic patients with matched data who were on aspirin monotherapy (50% vs. 0%; p=0.02), but the number of subjects in this subgroup analysis was very limited (N = 8; Table 3b ).
Platelet Reactivity in MES-positive and MES-negative subgroups:
Twenty-five asymptomatic, 31 early symptomatic and 27 late symptomatic patients had TCD data available for analysis. [19] As reported previously, 12% of asymptomatic vs. 32% of early symptomatic (p=0.02) and 19% late symptomatic patients (p=0.2) were MES +ve. [9, 19, 32] There were no significant differences in median C-EPI or C-ADP closure times between MES + ve vs. MES -ve subjects within the asymptomatic, early symptomatic, or late symptomatic subgroups (p≥0.16).
There were no significant differences in HTPR status between asymptomatic vs. early or late symptomatic MES +ve patients, or between asymptomatic vs. early or late symptomatic MES -ve patients (p≥0.32).
Relationship between HTPR status and clinical outcome events:
Interestingly, one of the 2 symptomatic patients who developed perioperative recurrent stroke was taking aspirin-clopidogrel combination therapy and displayed HTPR on both the C-ADP and C-EPI cartridges in the early stage. The other symptomatic patient with perioperative stroke did not have HTPR on aspirindipyridamole in the early stage. Therefore, one could not comment on any clear association between HTPR status and the incidence of recurrent vascular events due to the limited number of outcome events in this study.
Discussion
This novel, pilot study has revealed several interesting findings. The lack of differences in on-treatment platelet reactivity / platelet adhesion-aggregation on this moderately high shear stress device in asymptomatic vs. early symptomatic patients overall may partly reflect the fact that the stenosing atherosclerotic carotid plaque exposed circulating platelets to similar levels of shear stress in vivo in both patient groups initially [7, [33] [34] [35] [36] , and the PFA-100 was not sensitive enough at detecting differences between groups. The lack of significant differences in C-EPI closure times between asymptomatic and early symptomatic patients also likely reflects that fact that similar antiplatelet regimens were used in each group initially (predominantly aspirin), and C-EPI closure times are highly sensitive to the effects of aspirin. [7, 37] Although there were no statistically significant differences in on-treatment platelet reactivity between asymptomatic and late symptomatic patients overall, this likely reflects a type II error because there were non-significant trends towards more prolonged median C-EPI closure times and a lower prevalence of HTPR in late symptomatic compared with asymptomatic patients (table 2) . We do not think that these late symptomatic C-EPI results were likely to have been significantly influenced by the more frequent use of aspirin and dipyridamole combination therapy in late symptomatic than asymptomatic patients, because previous data from our group have shown that the addition of dipyridamole to aspirin may prolong C-ADP, but not C-EPI closure times following TIA or ischaemic stroke. [38] Our preliminary subgroup data suggest that successful interventional treatment may even reduce the prevalence of aspirin-HTPR, as measured on the C-EPI cartridge, in symptomatic patients to lower levels than in asymptomatic patients on aspirin monotherapy.
However, one must emphasise that this latter finding is subject to a type I error because the number of subjects included in this latter subgroup analysis was far too small to make any definitive conclusions; larger longitudinal studies are warranted to confirm or refute these potentially important subgroup findings.
The longitudinal C-EPI data in the symptomatic group are also interesting, and indicate that the prevalence of antiplatelet-HTPR falls as one is followed from the early to the late phase after symptom onset or intervention, including those on aspirin monotherapy. These results most likely partly reflect the effects of successful removal/treatment of the stenosing carotid plaque in the majority of symptomatic patients, as well as resolution of the acute phase response over time in patients treated with modern secondary preventive treatment. Larger, longitudinal studies assessing the same patients before and after changing antiplatelet therapy [38] are needed to adequately assess the impact of changing antiplatelet therapy on HTPR status in patients with carotid stenosis. Such studies will allow one to determine whether patients who exhibit a reduction in on-treatment platelet reactivity in response to commencing or changing antiplatelet treatment will have a lower risk of recurrent vascular events than patients who do not exhibit such a dynamic change.
Data from the C-ADP cartridge in patients on clopidogrel were not informative in this study. Our group and others have since shown that this cartridge is not sensitive to the anti-platelet effects if clopidogrel ex vivo when one uses a cross-sectional definition of clopidogrel-HTPR. [12, 30, 37] We chose to initially assess platelet function with the PFA-100 in this novel pilot study because platelets in patients with ≥50% carotid stenosis are believed to be exposed to at least moderate-high levels of shear stress in vivo. [33, 35] , and we wanted to mimic these shear stress conditions ex vivo. It is possible that one might derive more informative data on HTPR if one were to use an ex vivo test of platelet function that exposed platelets to low shear stress, variable levels of shear stress, or simply stirred the platelets in solution, to avoid excessive exposure of platelets to high shear stress both in vivo and ex vivo. These experiments are ongoing in our lab, and data are awaited.
We did not find significant differences in on-treatment platelet reactivity in MES +vs subjects when compared with MES -ve subjects with asymptomatic or symptomatic carotid stenosis. This may reflect a type I error because the number of subjects included in this study was relatively small, but as stated above, this device may not be sensitive enough at detecting differences in HTPR status between asymptomatic and symptomatic patients overall before they undergo intervention.
In conclusion, these pilot, proof-of-concept studies have shown that platelet function/reactivity monitoring with a moderately high shear stress testing platform may identify dynamic changes in HTPR status in symptomatic vs. asymptomatic moderate-severe carotid stenosis subgroups, and in symptomatic patients over time.
Larger, longitudinal studies are warranted to reassess the impact of more intensive secondary preventive and interventional treatment on ex vivo platelet function at different levels of shear stress to determine whether monitoring HTPR status may facilitate optimised, individualised stroke prevention in patients with carotid stenosis.
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